EXC Stock Cash Flow Statements
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Quarterly Cash Flow Statements
Quarterly
|
Annual
Unit: USD | 2023-03-31 | 2022-06-30 | 2022-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2013-03-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 |
---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities | ||||||||||
net income | 669,000,000 | 465,000,000 | 598,000,000 | 587,000,000 | 634,000,000 | 738,000,000 | 1,000,000 | 297,000,000 | 290,000,000 | 200,000,000 |
adjustments to reconcile net income to net cash flows from operating activities: | ||||||||||
depreciation, amortization, and accretion, including nuclear fuel and energy contract amortization | 860,000,000 | 830,000,000 | 1,024,000,000 | |||||||
gain on sales of assets and businesses | 2,000,000 | -10,000,000 | ||||||||
deferred income taxes and amortization of investment tax credits | 113,000,000 | 33,000,000 | 110,000,000 | 30,000,000 | 82,000,000 | 129,000,000 | -610,000,000 | 36,000,000 | 126,000,000 | 101,000,000 |
net fair value changes related to derivatives | 0 | -59,000,000 | 144,000,000 | -416,000,000 | -91,000,000 | 388,000,000 | -54,000,000 | -250,000,000 | -73,000,000 | |
net realized and unrealized losses on ndt funds | ||||||||||
net unrealized losses on equity investments | 16,000,000 | |||||||||
other non-cash operating activities | -138,000,000 | 44,000,000 | 232,000,000 | 277,000,000 | 235,000,000 | 344,000,000 | 231,000,000 | 276,000,000 | 429,000,000 | 530,000,000 |
changes in assets and liabilities: | ||||||||||
accounts receivable | 106,000,000 | -84,000,000 | -711,000,000 | -78,000,000 | 523,000,000 | -270,000,000 | -70,000,000 | -174,000,000 | 20,000,000 | 394,000,000 |
inventories | 102,000,000 | -113,000,000 | 125,000,000 | -94,000,000 | -132,000,000 | 291,000,000 | 101,000,000 | -33,000,000 | -59,000,000 | 104,000,000 |
accounts payable and accrued expenses | -482,000,000 | 253,000,000 | 291,000,000 | |||||||
option premiums paid | -3,000,000 | |||||||||
collateral (paid) received | -214,000,000 | |||||||||
income taxes | 23,000,000 | -54,000,000 | 77,000,000 | 53,000,000 | 73,000,000 | 174,000,000 | 632,000,000 | 206,000,000 | 81,000,000 | 178,000,000 |
regulatory assets and liabilities | -324,000,000 | |||||||||
pension and non-pension postretirement benefit contributions | -44,000,000 | -11,000,000 | -574,000,000 | -129,000,000 | -32,000,000 | -269,000,000 | -267,000,000 | -41,000,000 | -35,000,000 | -55,000,000 |
other assets and liabilities | -187,000,000 | -78,000,000 | -645,000,000 | -694,000,000 | 99,000,000 | 115,000,000 | 233,000,000 | -74,000,000 | -235,000,000 | -122,000,000 |
net cash flows from operating activities | 484,000,000 | 1,458,000,000 | 1,782,000,000 | 1,705,000,000 | 2,479,000,000 | 1,490,000,000 | 859,000,000 | 1,828,000,000 | 1,735,000,000 | 994,000,000 |
cash flows from investing activities | ||||||||||
capital expenditures | -1,881,000,000 | -1,585,000,000 | -1,922,000,000 | -1,983,000,000 | -1,676,000,000 | -1,784,000,000 | -1,447,000,000 | -1,329,000,000 | -1,320,000,000 | -1,496,000,000 |
proceeds from ndt fund sales | 0 | 488,000,000 | ||||||||
investment in ndt funds | 0 | -516,000,000 | ||||||||
collection of dpp | 0 | 169,000,000 | ||||||||
proceeds from sales of assets and businesses | 0 | 16,000,000 | ||||||||
other investing activities | 10,000,000 | 58,000,000 | -54,000,000 | -30,000,000 | -75,000,000 | -2,000,000 | 40,000,000 | 53,000,000 | 47,000,000 | -59,000,000 |
net cash flows used in investing activities | -1,871,000,000 | -2,143,000,000 | -1,795,000,000 | -1,751,000,000 | -1,471,000,000 | -1,341,000,000 | -1,344,000,000 | -640,000,000 | ||
cash flows from financing activities | ||||||||||
changes in short-term borrowings | -1,130,000,000 | 103,000,000 | -700,000,000 | 136,000,000 | 235,000,000 | -141,000,000 | ||||
proceeds from short-term borrowings with maturities greater than 90 days | 0 | 1,150,000,000 | ||||||||
repayments on short-term borrowings with maturities greater than 90 days | -150,000,000 | 0 | -350,000,000 | |||||||
issuance of long-term debt | 3,925,000,000 | 850,000,000 | 4,301,000,000 | 2,000,000 | 4,701,000,000 | 1,206,000,000 | 149,000,000 | 708,000,000 | ||
retirement of long-term debt | -857,000,000 | -1,701,000,000 | -6,000,000 | -37,000,000 | -1,128,000,000 | -580,000,000 | -1,000,000 | -82,000,000 | -198,000,000 | -451,000,000 |
dividends paid on common stock | -358,000,000 | -331,000,000 | -332,000,000 | -282,000,000 | -268,000,000 | -269,000,000 | -450,000,000 | -453,000,000 | -423,000,000 | -350,000,000 |
proceeds from employee stock plans | 10,000,000 | 8,000,000 | 9,000,000 | 8,000,000 | 8,000,000 | 8,000,000 | 12,000,000 | 19,000,000 | 30,000,000 | 12,000,000 |
transfer of cash, restricted cash, and cash equivalents to constellation | 0 | -2,594,000,000 | ||||||||
other financing activities | -60,000,000 | -22,000,000 | -62,000,000 | -6,000,000 | -43,000,000 | -16,000,000 | -45,000,000 | -10,000,000 | -9,000,000 | -1,000,000 |
net cash flows from financing activities | 1,380,000,000 | -1,093,000,000 | 1,416,000,000 | 1,689,000,000 | 3,505,000,000 | 208,000,000 | -136,000,000 | 237,000,000 | -649,000,000 | |
increase in cash, restricted cash, and cash equivalents | -7,000,000 | -1,162,000,000 | 1,379,000,000 | |||||||
cash, restricted cash, and cash equivalents at beginning of period | 1,090,000,000 | 0 | 1,619,000,000 | |||||||
cash, restricted cash, and cash equivalents at end of period | 1,083,000,000 | -1,162,000,000 | 2,998,000,000 | |||||||
supplemental cash flow information | ||||||||||
decrease in capital expenditures not paid | -201,000,000 | 46,000,000 | -322,000,000 | |||||||
increase in dpp | 0 | 348,000,000 | ||||||||
decrease in pp&e related to aro update | ||||||||||
asset impairments | ||||||||||
net realized and unrealized losses (gains) on ndt funds | 0 | 205,000,000 | ||||||||
net unrealized losses (gains) on equity investments | ||||||||||
option premiums (paid) received | 0 | -39,000,000 | -14,000,000 | -8,000,000 | -100,000,000 | |||||
collateral received | 547,000,000 | 1,142,000,000 | ||||||||
increase in pp&e related to aro update | 0 | -335,000,000 | ||||||||
net cash flows from investing activities | -1,819,000,000 | |||||||||
depreciation, amortization, depletion and accretion, including nuclear fuel and energy contract amortization | 973,000,000 | 1,009,000,000 | 948,000,000 | 1,017,000,000 | ||||||
impairment of long-lived assets | 1,000,000 | |||||||||
gain on consolidation and acquisition of businesses | ||||||||||
gain on sales of assets | -2,000,000 | -7,000,000 | -1,000,000 | |||||||
net realized and unrealized (gains) losses on nuclear decommissioning trust fund investments | ||||||||||
accounts payable, accrued expenses and other current liabilities | 521,000,000 | -61,000,000 | -607,000,000 | -542,000,000 | 226,000,000 | 113,000,000 | -1,176,000,000 | |||
option premiums received | 5,000,000 | 17,000,000 | 5,000,000 | |||||||
counterparty collateral received (posted) | -112,000,000 | 386,000,000 | 31,000,000 | -186,000,000 | -43,000,000 | 111,000,000 | 340,000,000 | |||
proceeds from nuclear decommissioning trust fund sales | 1,237,000,000 | 1,633,000,000 | 1,681,000,000 | 677,000,000 | 891,000,000 | 1,691,000,000 | 3,680,000,000 | |||
investment in nuclear decommissioning trust funds | -1,300,000,000 | -1,690,000,000 | -1,747,000,000 | -729,000,000 | -939,000,000 | -1,757,000,000 | -3,726,000,000 | |||
acquisition of businesses | 0 | -13,000,000 | -15,000,000 | |||||||
proceeds from sale of long-lived assets | 0 | 3,000,000 | 142,000,000 | |||||||
proceeds from termination of direct financing lease investment | ||||||||||
proceeds from sales of investments | 14,000,000 | 2,000,000 | 10,000,000 | |||||||
cash and restricted cash acquired from consolidations and acquisitions | ||||||||||
change in restricted cash | -67,000,000 | 23,000,000 | -26,000,000 | -12,000,000 | -23,000,000 | -7,000,000 | -8,000,000 | |||
issuance of common stock | ||||||||||
distributions to noncontrolling interest of consolidated vie | ||||||||||
increase in cash and cash equivalents | 1,251,000,000 | 351,000,000 | ||||||||
cash and cash equivalents at beginning of period | 0 | 0 | 1,878,000,000 | 1,486,000,000 | 0 | 0 | 1,016,000,000 | |||
cash and cash equivalents at end of period | 1,251,000,000 | 4,189,000,000 | 1,825,000,000 | 772,000,000 | 351,000,000 | 628,000,000 | 721,000,000 | |||
net realized and unrealized gains on nuclear decommissioning trust fund investments | 45,000,000 | -47,000,000 | -66,000,000 | 33,000,000 | -103,000,000 | |||||
decrease in cash and cash equivalents | -53,000,000 | -714,000,000 | -295,000,000 | |||||||
cash and restricted cash acquired from constellation | ||||||||||
changes in short-term debt | 233,000,000 | -318,000,000 | 38,000,000 | 141,000,000 | ||||||
net cash flows used in financing activities | -102,000,000 | |||||||||
depreciation, amortization, accretion and depletion including nuclear fuel and energy contract amortization | 1,014,000,000 | 1,119,000,000 | 776,000,000 | |||||||
impairment of assets held for sale | ||||||||||
acquisitions | ||||||||||
cash acquired from constellation | 0 | 0 | 964,000,000 | |||||||
purchases of investments | -8,000,000 | 0 | -5,000,000 | |||||||
dividends paid to former constellation shareholders | 0 |